

Rosa Lombardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/937384/publications.pdf>

Version: 2024-02-01

58
papers

1,669
citations

304743

22
h-index

302126

39
g-index

58
all docs

58
docs citations

58
times ranked

2837
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	2.0	10
2	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. <i>Journal of Internal Medicine</i> , 2022, 291, 374-376.	6.0	8
3	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 535-549.	4.3	18
4	Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 156-160.	1.5	1
5	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. <i>Biomedicines</i> , 2022, 10, 249.	3.2	16
6	Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. <i>Biomedicines</i> , 2022, 10, 182.	3.2	15
7	Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. <i>Nutrients</i> , 2022, 14, 556.	4.1	10
8	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2707.	4.1	9
9	MAFLD and CKD: An Updated Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7007.	4.1	11
10	Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity. <i>Internal and Emergency Medicine</i> , 2022, 17, 1739-1749.	2.0	5
11	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021, 53, 1301-1307.	0.9	6
12	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353.	2.6	40
13	Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature. <i>Livers</i> , 2021, 1, 132-137.	1.9	2
14	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 517-519.	4.4	12
15	High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results. <i>Digestive and Liver Disease</i> , 2020, 52, 84-90.	0.9	3
16	Liver fibrosis by FibroScan independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. <i>Liver International</i> , 2020, 40, 347-354.	3.9	59
17	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107684.	2.3	11
18	Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8761.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2408-2416.	4.4	58
20	Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?. <i>Digestive and Liver Disease</i> , 2020, 52, 470-471.	0.9	0
21	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020, 296, 40-47.	0.8	78
22	Combined use of Genetic Polymorphisms and Elastographic Techniques in NAFLD: Fact or Fiction?. <i>Current Pharmaceutical Design</i> , 2020, 26, 1010-1018.	1.9	4
23	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. <i>Liver International</i> , 2019, 39, 2309-2316.	3.9	8
24	THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. <i>Journal of Hepatology</i> , 2019, 70, e302.	3.7	0
25	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 158523.	2.4	17
26	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1135-1140.	0.9	18
27	Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 1214-1222.	0.9	52
28	Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 474-480.	2.1	18
29	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
30	Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis. <i>Internal and Emergency Medicine</i> , 2019, 14, 763-766.	2.0	0
31	A sweet fever. <i>Internal and Emergency Medicine</i> , 2019, 14, 1125-1128.	2.0	0
32	Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease. <i>Metabolic Brain Disease</i> , 2018, 33, 347-352.	2.9	4
33	Role of nutritional intake on clinical presentation of lean and overweight NAFLD. <i>Journal of Hepatology</i> , 2018, 68, S837.	3.7	0
34	Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. <i>Atherosclerosis</i> , 2018, 268, 27-31.	0.8	19
35	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1604-1611.e1.	4.4	146
36	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD). <i>The Cochrane Library</i> , 2017, 2017, CD011640.	2.8	36

#	ARTICLE	IF	CITATIONS
37	Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. <i>Annals of Gastroenterology</i> , 2017, 30, 349-356.	0.6	16
38	Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. <i>International Journal of Molecular Sciences</i> , 2016, 17, 675.	4.1	12
39	Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. <i>International Journal of Molecular Sciences</i> , 2016, 17, 548.	4.1	58
40	Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. <i>Digestive and Liver Disease</i> , 2016, 48, 1471-1477.	0.9	45
41	Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. <i>Drugs and Aging</i> , 2016, 33, 53-61.	2.7	24
42	Progressively invalidating orthostatic hypotension: A common symptom for a challenging diagnosis. <i>Journal of Research in Medical Sciences</i> , 2016, 21, 117.	0.9	1
43	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11044.	3.3	25
44	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	1.5	41
45	The <i>UCP2</i> promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 1574-1580.	3.9	41
46	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. <i>Internal and Emergency Medicine</i> , 2015, 10, 305-313.	2.0	7
47	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2015, 26, 243-249.	2.2	14
48	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. <i>European Journal of Internal Medicine</i> , 2015, 26, 330-337.	2.2	25
49	Global Epidemiology of Hepatitis B Virus (HBV) Infection. <i>Current Hepatology Reports</i> , 2015, 14, 171-178.	0.9	31
50	Extrapulmonary tuberculosis: an unusual presentation in an immunocompetent patient. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207146-bcr2014207146.	0.5	5
51	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. <i>Internal and Emergency Medicine</i> , 2014, 9, 723-734.	2.0	121
52	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. <i>European Journal of Internal Medicine</i> , 2014, 25, 847-852.	2.2	1
53	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2014, 25, 617-623.	2.2	75
54	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. <i>Internal and Emergency Medicine</i> , 2013, 8, 509-520.	2.0	23

#	ARTICLE	IF	CITATIONS
55	Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013, 24, 800-806.	2.2	12
56	PNPLA3 I148M polymorphism and progressive liver disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 6969.	3.3	207
57	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. <i>Journal of Hepatology</i> , 2011, 54, 1244-1249.	3.7	107
58	Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Exploration of Medicine</i> , 0, , .	1.5	0